SciELO - Scientific Electronic Library Online

 
vol.27 issue3Ureteral obstruction after renal transplantation: treatment with metallic self-expandable stentFinasteride: ten years of clinical use. Sistematic revision of biblioghraphy author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Actas Urológicas Españolas

Print version ISSN 0210-4806

Abstract

MILLAN RODRIGUEZ, F.; ROUSAUD BARON, F.  and  ROUSAUD BARON, A.. Model study of the treatment of recurrent cystitis in women by means of AM3 (Inmunoferon®). Actas Urol Esp [online]. 2003, vol.27, n.3, pp.196-201. ISSN 0210-4806.

OBJECTIVES: The aim is to evaluate the effectiveness of AM3 (Inmunoferon®) in the treatment of the recurrent cystitis in women in order to know the rate of good results, previously to design a clinical trial. MATERIAL AND METHODS: Twenty-four women who had been diagnosed of two cystitis episodes in the previous 6 months without cure by antibiotic treatment were admitted to the study. Standard antibiotic treatment and 3 daily grammes of AM3 was given for 9 months. Infection and irritative symptoms during micturition rate were evaluated at the inclusion date and afterwards, at the first, third, sixth and nineth month. RESULTS: Nineteen patients finished the study. The infection rate decreased from 100% at the inclusion date to 26% in the first month and then it became stable about 50%. Irritative symptoms during micturition decreased from 46% at the inclusion date to a rate lower than 10% in the 4 controls running. CONCLUSION: AM3 reduced evident urinary infection in a 50% and irritative symptoms during micturition in a 90%. Control clinical trials are needed to confirm the AM3 effects on this pathology.

Keywords : Recurrent cystitis; AM3; Inmunoferon®.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License